(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 18.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.28%.
Bioage Labs's earnings in 2026 is -$94,464,000.On average, 12 Wall Street analysts forecast BIOA's earnings for 2026 to be -$119,717,497, with the lowest BIOA earnings forecast at -$136,736,071, and the highest BIOA earnings forecast at -$102,166,519. On average, 12 Wall Street analysts forecast BIOA's earnings for 2027 to be -$95,635,389, with the lowest BIOA earnings forecast at -$135,836,492, and the highest BIOA earnings forecast at $55,420,518.
In 2028, BIOA is forecast to generate -$128,346,116 in earnings, with the lowest earnings forecast at -$150,408,760 and the highest earnings forecast at -$101,684,602.